iStent® Trabecular Micro-Bypass Stent Reduced IOP And Medication Use In Predominately Hispanic Glaucoma Patient Population, According To Published Study

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a study of 134 predominantly Hispanic eyes with open-angle glaucoma (OAG), published in Clinical Ophthalmology, showed mean intraocular pressure (IOP) of 12.9 mm Hg and a 61% decrease in mean medication burden one year following implantation of the iStent® Trabecul...